» Articles » PMID: 39008186

Dual Roles of Myeloid-derived Suppressor Cells in Various Diseases: a Review

Overview
Journal Arch Pharm Res
Specialty Pharmacology
Date 2024 Jul 15
PMID 39008186
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that originate from bone marrow stem cells. In pathological conditions, such as autoimmune disorders, allergies, infections, and cancer, normal myelopoiesis is altered to facilitate the formation of MDSCs. MDSCs were first shown to promote cancer initiation and progression by immunosuppression with the assistance of various chemokines and cytokines. Recently, various studies have demonstrated that MDSCs play two distinct roles depending on the physiological and pathological conditions. MDSCs have protective roles in autoimmune disorders (such as uveoretinitis, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, type 1 diabetes, autoimmune hepatitis, inflammatory bowel disease, alopecia areata, and systemic lupus erythematosus), allergies, and organ transplantation. However, they play negative roles in infections and various cancers. Several immunosuppressive functions and mechanisms of MDSCs have been determined in different disease conditions. This review comprehensively discusses the associations between MDSCs and various pathological conditions and briefly describes therapeutic approaches.

Citing Articles

Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.

Eren E, Das J, Tollefsbol T Nutrients. 2024; 16(23).

PMID: 39683540 PMC: 11644657. DOI: 10.3390/nu16234143.


Myeloid-Derived Suppressor Cells (MDSCs) and Obesity-Induced Inflammation in Type 2 Diabetes.

Ghemis L, Goriuc A, Minea B, Botnariu G, Martu M, Entuc M Diagnostics (Basel). 2024; 14(21).

PMID: 39518420 PMC: 11544947. DOI: 10.3390/diagnostics14212453.

References
1.
An J, Feng L, Ren J, Li Y, Li G, Liu C . Chronic stress promotes breast carcinoma metastasis by accumulating myeloid-derived suppressor cells through activating β-adrenergic signaling. Oncoimmunology. 2021; 10(1):2004659. PMC: 8632282. DOI: 10.1080/2162402X.2021.2004659. View

2.
Apte R, Voronov E . Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?. Immunol Rev. 2008; 222:222-41. DOI: 10.1111/j.1600-065X.2008.00615.x. View

3.
Arora M, Poe S, Ray A, Ray P . LPS-induced CD11b+Gr1(int)F4/80+ regulatory myeloid cells suppress allergen-induced airway inflammation. Int Immunopharmacol. 2011; 11(7):827-32. PMC: 3109207. DOI: 10.1016/j.intimp.2011.01.034. View

4.
Awad R, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K . Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol. 2018; 9:1977. PMC: 6127274. DOI: 10.3389/fimmu.2018.01977. View

5.
Ba H, Li B, Li X, Li C, Feng A, Zhu Y . Transmembrane tumor necrosis factor-α promotes the recruitment of MDSCs to tumor tissue by upregulating CXCR4 expression via TNFR2. Int Immunopharmacol. 2017; 44:143-152. DOI: 10.1016/j.intimp.2016.12.028. View